Early redemption of convertible bonds (incl. overseas CBs)

What happened

Aptabio Therapeutics / Early redemption of convertible bonds (incl. overseas CBs) / (2026.08.24) Early redemption of convertible bonds (incl. overseas CBs) before maturity

Early Redemption of Convertible Bonds (incl. Overseas CBs) Before Maturity Convertible Bonds (incl. Overseas CBs), Series 1

1. Details of the bonds acquired before maturity Type of bonds: Unregistered, interest-bearing, unsecured, privately placed convertible bonds Date of issuance: 2023-08-24 Issuance method: Domestic issuance (private placement) Conversion price per share (KRW): 7,240 Maturity date: 2028-08-24

2. Bond acquisition amount (currency unit): 4,858,264,242 KRW: South-Korean Won - Total face (electronically registered) amount of bonds acquired (currency unit): 4,446,000,000 KRW: South-Korean Won - Applicable exchange rate: not applicable - Acquisition date: 2026-08-24

3. Total face (electronically registered) amount of bonds outstanding after acquisition (currency unit): 2,798,919,200 KRW: South-Korean Won

4. Reason for acquisition before maturity and future treatment - Reason: Acquisition before maturity following the bondholder's exercise of the early-redemption (put) option - Treatment: To be retired (deregistered with the Korea Securities Depository) - The above acquisition date is the date the acquisition amount was paid.

5. Source of acquisition funds: Own funds

6. Method of acquiring the bonds: Off-exchange purchase

7. Other matters material to investment decisions - The above conversion price per share (KRW) is the price as adjusted effective July 24, 2026. - The above bond acquisition amount includes both principal and interest. - The above acquisition date is the date the acquisition amount was paid.

* Related disclosures 2023-08-16 Decision to issue convertible bonds (Series 1)